To seek more efficient treatment drugs for CDK12‐deficient prostate cancer, we examined the response of pan‐cancer cell lines with CDK12 mutations to different medications in the Genomics of Drug Sensitivity in Cancer database. This evidence concerns the gene CDK12 and Familial prostate cancer.